Reducing Infarct Size in The Setting of Acute Myocardial Infarction

Progress in Cardiovascular Diseases

Volumn 48, Issue 5, 2006, Pages 363-371

  Downey, James M ^a   Cohen, Michael V ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; AUTACOID; BLOCKING AGENT; BONGKREKIC ACID; BRADYKININ; CALCIUM ION; CARIPORIDE; CYCLOPHILIN; CYCLOPHILIN D; CYCLOSPORIN A; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; OPIATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POTASSIUM; PROTECTIVE AGENT; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SANGLIFEHRIN A; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACIDOSIS; ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM DEPLETION; CHANNEL GATING; CLINICAL PRACTICE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; HYPOKALEMIA; HYPOTENSION; HYPOTHESIS; ISCHEMIC PRECONDITIONING; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NONHUMAN; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; UNSTABLE ANGINA PECTORIS;

ANIMALS; DISEASE PROGRESSION; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 33646065940     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2006.02.005     Document Type: Article

References (41)

1. Maroko P.R., Kjekshus J.K., Sobel B.E., et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43 (1971) 67-82
2. Reimer K.A., and Jennings R.B. Can we really quantitate myocardial cell injury?. In: Hearse D.J., and Yellon D.M. (Eds). Therapeutic Approaches to Myocardial Infarct Size Limitation (1984), Raven Press, New York 163-184
3. Reimer K.A., Lowe J.E., Rasmussen M.M., et al. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56 (1977) 786-794
4. Reimer K.A., and Jennings R.B. The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab. Invest. 40 (1979) 633-644
5. Hearse D.J., Yellon D.M., and Downey J.M. Can beta blockers limit myocardial infarct size?. Eur. Heart J. 7 (1986) 925-930
6. Hearse D.J., Humphrey S.M., and Chain E.B. Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: A study of myocardial enzyme release. J. Mol. Cell. Cardiol. 5 (1973) 395-407
7. Reimer K.A., Murry C.E., and Richard V.J. The role of neutrophils and free radicals in the ischemic-reperfused heart: Why the confusion and controversy?. J. Mol. Cell. Cardiol. 21 (1989) 1225-1239
8. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
9. Yellon D.M., and Downey J.M. Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol. Rev. 83 (2003) 1113-1151
10. Hausenloy D.J., Tsang A., Mocanu M.M., et al. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. 288 (2005) H971-H976
11. Hausenloy D.J., Maddock H.L., Baxter G.F., et al. Inhibiting mitochondrial permeability transition pore opening: A new paradigm for myocardial preconditioning?. Cardiovasc. Res. 55 (2002) 534-543
12. Hausenloy D.J., and Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: Targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res. 61 (2004) 448-460
13. Halestrap A.P., Clarke S.J., and Javadov S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc. Res. 61 (2004) 372-385
14. Duchen M.R., McGuinness O., Brown L.A., et al. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc. Res. 27 (1993) 1790-1794
15. Kerr P.M., Suleiman M.-S., and Halestrap A.P. Reversal of permeability transition during recovery of hearts from ischemia and its enhancement by pyruvate. Am. J. Physiol. 276 (1999) H496-H502
16. Baxter G.F., Mocanu M.M., Brar B.K., et al. Cardioprotective effects of transforming growth factor-β1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J. Cardiovasc. Pharmacol. 38 (2001) 930-939
17. ATP channels in the isolated rabbit heart. Basic Res. Cardiol. 94 (1999) 188-198
18. Jonassen A.K., Sack M.N., Mjøs O.D., et al. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ. Res. 89 (2001) 1191-1198
19. 2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J. Pharmacol. Exp. Ther. 286 (1998) 611-618
20. Xu Z., Yang X.-M., Cohen M.V., et al. Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion. J. Mol. Cell. Cardiol. 32 (2000) 2339-2347
21. Baxter G.F., Ebrahim Z., and Yellon D.M. Amp579, an A1/A2A agonist, limits infarct size at reperfusion via a p42/p44 MAPK-dependent pathway. Circulation 102 Suppl II (2000) II-212
22. Budde J.M., Velez D.A., Zhao Z.-Q., et al. Comparative study of AMP579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc. Res. 47 (2000) 294-305
23. Bell R.M., and Yellon D.M. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: The role of PI3K, Akt and eNOS. J. Mol. Cell. Cardiol. 35 (2003) 185-193
24. Zhao Z.-Q., Corvera J.S., Halkos M.E., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am. J. Physiol. 285 (2003) H579-H588
25. Tsang A., Hausenloy D.J., Mocanu M.M., et al. Postconditioning: A form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ. Res. 95 (2004) 230-232
26. Yang X.-M., Proctor J.B., Cui L., et al. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J. Am. Coll. Cardiol. 44 (2004) 1103-1110
27. Solenkova N.V., Solodushko V., Cohen M.V., et al. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am. J. Physiol. 290 (2006) H449-H471
28. Yang X.-M., Philipp S., Downey J.M., et al. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res. Cardiol. 100 (2005) 57-63
29. Kin H., Zatta A.J., Lofye M.T., et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc. Res. 67 (2005) 124-133
30. 2b receptor cascade. Cardiovascular Res (in press).
31. Xu Z., Downey J.M., and Cohen M.V. Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis. 5 (2003) 368-371
32. Kopecky S.L., Aviles R.J., Bell M.R., et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: The ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am. Heart J. 146 (2003) 146-152
33. Sodi Pallares D., Ponce de Léon J., Bisteni A., et al. Potassium, glucose, and insulin in myocardial infarction. Lancet 1 (1969) 1315-1316
34. Prather J.W., Russell Jr. R.O., Mantle J.A., et al. Metabolic consequences of glucose-insulin-potassium infusion in treatment of acute myocardial infarction. Am. J. Cardiol. 38 (1976) 95-99
35. Jonassen A.K., Aasum E., Riemersma R.A., et al. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc. Drugs Ther. 14 (2000) 615-623
36. Mehta S.R., Yusuf S., Diaz R., et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: The CREATE-ECLA randomized controlled trial. JAMA 293 (2005) 437-446
37. Zhang S.J., Yang X.-M., Liu G.S., et al. CGX-1051, a peptide from Conus snail venom, attenuates infarction in rabbit hearts when administered at reperfusion. J. Cardiovasc. Pharmacol. 42 (2003) 764-771
38. Parsa C.J., Kim J., Riel R.U., et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: A potential role for cardiac fibroblasts. J. Biol. Chem. 279 (2004) 20655-20662
39. Dixon S.R., Whitbourn R.J., Dae M.W., et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J. Am. Coll. Cardiol. 40 (2002) 1928-1934
40. Théroux P., Chaitman B.R., Danchin N., et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Circulation 102 (2000) 3032-3038
41. Shen Y.-T., Fallon J.T., Iwase M., et al. Innate protection of baboon myocardium: Effects of coronary artery occlusion and reperfusion. Am. J. Physiol. 270 (1996) H1812-H1818